<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03877406</url>
  </required_header>
  <id_info>
    <org_study_id>B-1507/307-007</org_study_id>
    <nct_id>NCT03877406</nct_id>
  </id_info>
  <brief_title>Effect of Empagliflozin on Body Composition and Ketones</brief_title>
  <official_title>Decrease in Body Fat and Increase in Ketone Body After 6-month Treatment of Empagliflozin in Korean Patients With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Bundang Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate changes of body composition induced by
      Sodium-glucose cotransporter-2 (SGLT2) inhibitor and its metabolic consequence in Korean type
      2 diabetes (T2D).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sodium-glucose cotransporter-2 (SGLT2) inhibitor increases urinary excretion of glucose,
      promoting glycemic control and weight loss. However, it is unclear whether weight loss is
      attributed to decrease in fat components and associated with favorable changes in metabolic
      profile. The purpose of this study is to evaluate changes of body composition induced by
      SGLT2 inhibitor and its metabolic consequence in Korean type 2 diabetes (T2D).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HbA1c</measure>
    <time_frame>6 months</time_frame>
    <description>glycemic control</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biochemical parameters</measure>
    <time_frame>6 months</time_frame>
    <description>Ketone body concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body weight</measure>
    <time_frame>6 months</time_frame>
    <description>Weight change</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body fat</measure>
    <time_frame>6 months</time_frame>
    <description>fat change</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic and diastolic blood pressures</measure>
    <time_frame>6 months</time_frame>
    <description>blood pressure change</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid profile</measure>
    <time_frame>6 months</time_frame>
    <description>Triglyceride</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin resistance</measure>
    <time_frame>6 months</time_frame>
    <description>HOMA-IR</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Diabetes Mellitus</condition>
  <condition>Fat; Intolerance, Pancreas</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>up-titration of standard medication including monotherapy or combination of Metformin, Sulfonylurea, DPP4 inhibitor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>addition of empagliflozin 10mg qd on standard oral antihyperglycemic agents</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin 10 MG</intervention_name>
    <description>addition of empagliflozin 10 MG</description>
    <arm_group_label>Study group</arm_group_label>
    <other_name>SGLT2 inhibitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hypoglycemics Oral</intervention_name>
    <description>dose escalation of hypoglycemics oral</description>
    <arm_group_label>Control group</arm_group_label>
    <other_name>Oral antidiabetic medication escalation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients with type 2 diabetes Age: 20-79 years BMI ≥ 20 kg/m2 eGFR ≥ 45

        Exclusion Criteria:

        Patients with type 1 diabetes Secondary diabetes due to Cushing diseases, acromegaly
        Insulin user BMI &lt; 20 kg/m2 eGFR &lt; 45 Malignancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Soo N Lim, MD, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Bundang Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yujin N Shin, MD</last_name>
    <phone>82-31-787-7035</phone>
    <phone_ext>82317877035</phone_ext>
    <email>54256@snubh.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Soo N Lim</last_name>
    <phone>82317877035</phone>
    <phone_ext>82317877035</phone_ext>
    <email>limsoo@snu.ac.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <state>Gyeonggi</state>
        <zip>463-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Soo Lim, MD, PHD</last_name>
      <phone>82-31-787-7035</phone>
      <email>limsoo@snu.ac.kr</email>
    </contact>
    <contact_backup>
      <last_name>Yujin Shin, MD</last_name>
      <phone>82-31-787-6232</phone>
      <email>54256@snubh.org</email>
    </contact_backup>
    <investigator>
      <last_name>Soo Lim, MD, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>October 23, 2018</study_first_submitted>
  <study_first_submitted_qc>March 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2019</study_first_posted>
  <last_update_submitted>April 6, 2020</last_update_submitted>
  <last_update_submitted_qc>April 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Bundang Hospital</investigator_affiliation>
    <investigator_full_name>Soo Lim</investigator_full_name>
    <investigator_title>Professor, Division Chief of Endocrinology and Metabolism</investigator_title>
  </responsible_party>
  <keyword>Sodium-glucose transporter 2 inhibitor</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
    <mesh_term>Sodium-Glucose Transporter 2 Inhibitors</mesh_term>
    <mesh_term>Hypoglycemic Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

